CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,260,589 | +66.8% | 3,640,235 | +1.1% | 0.02% | +83.3% |
| Q2 2023 | $64,902,849 | +11.2% | 3,601,712 | -0.9% | 0.01% | 0.0% |
| Q1 2023 | $58,386,547 | +13.8% | 3,635,526 | +29.6% | 0.01% | +20.0% |
| Q4 2022 | $51,322,076 | -0.8% | 2,804,485 | +6.5% | 0.01% | -9.1% |
| Q3 2022 | $51,713,000 | +52.1% | 2,633,011 | +44.4% | 0.01% | +57.1% |
| Q2 2022 | $34,010,000 | +50.5% | 1,823,598 | +77.2% | 0.01% | +75.0% |
| Q1 2022 | $22,595,000 | -25.7% | 1,029,364 | -3.8% | 0.00% | -20.0% |
| Q4 2021 | $30,407,000 | +58.2% | 1,070,272 | +17.2% | 0.01% | +66.7% |
| Q3 2021 | $19,220,000 | +36.8% | 913,071 | +22.5% | 0.00% | +50.0% |
| Q2 2021 | $14,051,000 | +66.5% | 745,387 | +35.0% | 0.00% | +100.0% |
| Q1 2021 | $8,437,000 | +7.4% | 552,167 | -0.8% | 0.00% | 0.0% |
| Q4 2020 | $7,854,000 | +14.5% | 556,635 | +27.2% | 0.00% | 0.0% |
| Q3 2020 | $6,860,000 | +25.8% | 437,756 | +40.6% | 0.00% | 0.0% |
| Q2 2020 | $5,453,000 | – | 311,281 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $84,379,000 | 7.91% |
| RA Capital Management | 1,875,209 | $46,880,000 | 2.52% |
| Perceptive Advisors | 2,587,953 | $64,698,000 | 1.48% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $4,193,000 | 1.12% |
| Orbimed Advisors | 2,039,282 | $50,982,000 | 0.79% |
| Eventide Asset Management | 803,839 | $20,096,000 | 0.61% |
| Novo Holdings A/S | 135,009 | $3,375,000 | 0.47% |
| Opaleye Management Inc. | 36,000 | $900,000 | 0.27% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 490,000 | $12,250,000 | 0.03% |
| Baker Brothers Advisors | 132,985 | $3,325,000 | 0.02% |